We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

ELEKTA

Elekta develops tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well a... read more Featured Products: More products

Download Mobile App




Cancer Treatment Equipment and Software Upgrade for Hospitals in Austria

By MedImaging International staff writers
Posted on 25 Jul 2016
Image: The Versa HD advanced radiotherapy system used for cancer treatment (Photo courtesy of Elekta).
Image: The Versa HD advanced radiotherapy system used for cancer treatment (Photo courtesy of Elekta).
A contract has been signed for the installation of advanced radiation therapy and related software solutions in two new radiation oncology centers in Vienna.

The public-private partnership contract will include the installation of six linear accelerators. The equipment will be installed over a period of two years beginning with the first shipment in May 2017.

The contract is between the Vienna Hospital Association (KAV; Vienna, Austria) and Elekta (Stockholm, Sweden), and will consist of four Versa HD, and two Elekta Infinity linear accelerators, the MOSAIQ oncology information system, the Monaco treatment planning system, and brachytherapy afterloaders. The deal also includes long-term service contracts.

The Vienna Hospital Association is one of the largest operators of hospitals in Europe, and includes geriatric centers, and hospitals in Vienna.

Elekta is a human care company that develops treatment planning systems and tools for radiation therapy, radiosurgery, brachytherapy, and brain disorders. Elekta also develops workflow enhancement software for cancer care.

Ian Alexander, COO, Elekta, said, “Almost 40,000 people are diagnosed with cancer in Austria each year and it’s the second most common cause of death in the country. Studies have proven that radiation therapy is an effective treatment for cancer, even if it cannot save every patient. We are grateful to be able to make an impact on these statistics and the patients at the Vienna Hospital Association by improving or saving lives.”

Related Links:
Vienna Hospital Association
Elekta
Half Apron
Demi
Portable X-ray Unit
AJEX140H
Biopsy Software
Affirm® Contrast
Mammo DR Retrofit Solution
DR Retrofit Mammography

Channels

Nuclear Medicine

view channel
Image: The new tracer, 64Cu-NOTA-EV-F(ab′)2​, targets nectin-4, a protein strongly linked to tumor growth in both TNBC and UBC cancer types. (Wenpeng Huang et al., DOI: 10.2967/jnumed.125.270132)

PET Tracer Enables Same-Day Imaging of Triple-Negative Breast and Urothelial Cancers

Triple-negative breast cancer (TNBC) and urothelial bladder carcinoma (UBC) are aggressive cancers often diagnosed at advanced stages, leaving limited time for effective treatment decisions.... Read more

General/Advanced Imaging

view channel
Image: Concept of the photo-thermoresponsive SCNPs (J F Thümmler et al., Commun Chem (2025). DOI: 10.1038/s42004-025-01518-x)

New Ultrasmall, Light-Sensitive Nanoparticles Could Serve as Contrast Agents

Medical imaging technologies face ongoing challenges in capturing accurate, detailed views of internal processes, especially in conditions like cancer, where tracking disease development and treatment... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.